Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on "Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891-9895"

Curr Oncol. 2023 May 16;30(5):5050-5053. doi: 10.3390/curroncol30050381.

¹ Division of Medical Oncology, Department of Medicine, Queen Elizabeth II Health Sciences Center, Halifax, NS B3H 2Y9, Canada.
² Division of Medical Oncology/Hematology, Odette Cancer Centre Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
³ Division of Medical Oncology, Cross Cancer Institute, Edmonton, AB T6G 1Z2, Canada.
⁴ Division of Medical Oncology, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada.
⁵ Division of Medical Oncology, British Columbia Cancer Centre, Vancouver, BC V5Z 4E6, Canada.
⁶ Department of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada.
⁷ Department of Medical Oncology, University Health Network, Toronto, ON M5G 1Z5, Canada.

Abstract

We appreciate the opportunity to respond to the comment [...].